Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
Incyte Corp granted long‑term equity awards to its Executive Vice President of Human Resources consisting of 6,506 restricted stock units that vest 25% annually, 16,265 performance shares, and 29,230 stock options
Ramitpal K. Basi, serving as EVP, Human Resources of Incyte Corp (INCY), filed an initial Form 3 reporting the date triggering the filing as 08/25/2025. The filing states no securities are beneficially owned by the reporting person as of that date. The Form 3 shows the filing was executed on behalf of the reporting person by an attorney-in-fact, Elizabeth Feeney, with a signature date of 08/27/2025. This is a routine Section 16 initial ownership disclosure indicating the officer held no reportable shares or derivative positions at the event date.
Sheila A. Denton, EVP & General Counsel of Incyte Corp. (INCY), reported insider option activity under a written trading plan. The report shows Denton exercised 277 employee stock options with a $64.25 exercise price and simultaneously sold 277 shares at $86.81, leaving her beneficial ownership around 33,200 shares when including unvested restricted stock and performance units. The filing indicates an affirmative-defense trading plan consistent with Rule 10b5-1 and discloses remaining employee option holdings that become exercisable/vest under previously reported schedules.
Incyte Genomics Inc (INCY) filed a Form 144 reporting a proposed sale of 277 common shares on 08/15/2025 through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $24,046.37 and shows 195,276,145 shares outstanding, and the shares were acquired the same day via a stock option exercise with payment in cash.
The filing also discloses five recent sales by Sheila Denton within the prior three months: 1,795 shares on 06/03/2025; 599 on 07/02/2025; 3,330 on 07/15/2025; 785 on 07/16/2025; and 598 on 08/04/2025, with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information and the form identifies Morgan Stanley as broker of record.
Incyte Genomics' Form 144 records a proposed sale of 75,963 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $6,267,540.00. The shares were acquired via a stock option exercise on 08/13/2025 and payment was made in cash.
The filing also lists insider sales by Barry Flannelly totaling 27,472 shares in the past three months for gross proceeds of $2,040,893.53. The issuer reports 195,276,145 shares outstanding, so the proposed sale equals approximately 0.039% of outstanding shares. The document contains no earnings, guidance, or other operational details.
Incyte Genomics' Form 144 discloses a proposed sale of 14,037 common shares with an aggregate market value of $1,122,969.83, to be sold through Morgan Stanley Smith Barney on 08/12/2025 on NASDAQ. The filing states these shares were acquired on 08/12/2025 through a stock option exercise and paid for in cash.
The notice also lists recent sales by BARRY FLANNELLY totaling 13,435 shares in July 2025, generating gross proceeds of $917,923.70. The filing shows 195,276,145 shares outstanding and includes the filer's certification that they do not possess undisclosed material adverse information.
Form 3 filing snapshot: On 21 Jul 2025 Patrick A. Mayes—newly appointed EVP & Chief Scientific Officer of Incyte Corp. (INCY)—submitted his initial statement of beneficial ownership.
- Direct equity: 67,388 common shares, the bulk of which are restricted stock units scheduled to vest between 2025-2028.
- Derivative exposure: 57,080 employee stock options across 15 grants; strike prices range from $61.18 to $106.47 with expirations from 2027-2035. Most awards are either fully vested or vest monthly/annually over four years.
The filing establishes Mayes as a Section 16 insider and documents equity-based incentives that align his compensation with shareholder value. No purchases or sales occurred, so immediate market impact is minimal.